JP2020504763A - メチルフェニデートを用いてadhdを処置するための小児の有効な投薬 - Google Patents
メチルフェニデートを用いてadhdを処置するための小児の有効な投薬 Download PDFInfo
- Publication number
- JP2020504763A JP2020504763A JP2019544799A JP2019544799A JP2020504763A JP 2020504763 A JP2020504763 A JP 2020504763A JP 2019544799 A JP2019544799 A JP 2019544799A JP 2019544799 A JP2019544799 A JP 2019544799A JP 2020504763 A JP2020504763 A JP 2020504763A
- Authority
- JP
- Japan
- Prior art keywords
- methylphenidate
- drug
- individual patient
- weight
- auc
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
- G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H70/00—ICT specially adapted for the handling or processing of medical references
- G16H70/40—ICT specially adapted for the handling or processing of medical references relating to drugs, e.g. their side effects or intended usage
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Medicinal Preparation (AREA)
- General Physics & Mathematics (AREA)
- Hematology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Food Science & Technology (AREA)
- Urology & Nephrology (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Medical Informatics (AREA)
- Primary Health Care (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662415884P | 2016-11-01 | 2016-11-01 | |
| US62/415,884 | 2016-11-01 | ||
| PCT/US2017/059256 WO2018085256A1 (en) | 2016-11-01 | 2017-10-31 | Effective dosing of a child for the treatment of adhd with methylphenidate |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020504763A true JP2020504763A (ja) | 2020-02-13 |
| JP2020504763A5 JP2020504763A5 (enExample) | 2020-12-10 |
Family
ID=62076554
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019544799A Pending JP2020504763A (ja) | 2016-11-01 | 2017-10-31 | メチルフェニデートを用いてadhdを処置するための小児の有効な投薬 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US11166947B2 (enExample) |
| EP (1) | EP3585439A4 (enExample) |
| JP (1) | JP2020504763A (enExample) |
| KR (2) | KR20240033130A (enExample) |
| AU (1) | AU2017353921B2 (enExample) |
| WO (1) | WO2018085256A1 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2023518871A (ja) * | 2020-03-23 | 2023-05-08 | ジェネンテック, インコーポレイテッド | 深層学習を使用した薬物動態パラメータの推定 |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12303604B1 (en) | 2024-10-16 | 2025-05-20 | Currax Pharmaceuticals Llc | Pharmaceutical formulations comprising naltrexone and/or bupropion |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013003622A1 (en) * | 2011-06-28 | 2013-01-03 | Neos Therapeutics, Lp | Dosage forms for oral administration and methods of treatment using the same |
| US20140287041A1 (en) * | 2012-08-15 | 2014-09-25 | Tris Pharma Inc | Methylphenidate Extended Release Chewable Tablet |
| WO2015188092A1 (en) * | 2014-06-06 | 2015-12-10 | Rhodes Pharmaceuticals, L.P. | Methods for treating attention deficit hyperactivity disorder with methylphenidate |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060240105A1 (en) | 1998-11-02 | 2006-10-26 | Elan Corporation, Plc | Multiparticulate modified release composition |
| CA2348871C (en) * | 1998-11-02 | 2009-04-14 | John G. Devane | Multiparticulate modified release composition |
| US6344215B1 (en) | 2000-10-27 | 2002-02-05 | Eurand America, Inc. | Methylphenidate modified release formulations |
-
2017
- 2017-10-31 JP JP2019544799A patent/JP2020504763A/ja active Pending
- 2017-10-31 KR KR1020247006668A patent/KR20240033130A/ko active Pending
- 2017-10-31 AU AU2017353921A patent/AU2017353921B2/en active Active
- 2017-10-31 KR KR1020197015402A patent/KR20190107655A/ko not_active Ceased
- 2017-10-31 US US16/346,850 patent/US11166947B2/en active Active
- 2017-10-31 WO PCT/US2017/059256 patent/WO2018085256A1/en not_active Ceased
- 2017-10-31 EP EP17868418.9A patent/EP3585439A4/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013003622A1 (en) * | 2011-06-28 | 2013-01-03 | Neos Therapeutics, Lp | Dosage forms for oral administration and methods of treatment using the same |
| US20140287041A1 (en) * | 2012-08-15 | 2014-09-25 | Tris Pharma Inc | Methylphenidate Extended Release Chewable Tablet |
| WO2015188092A1 (en) * | 2014-06-06 | 2015-12-10 | Rhodes Pharmaceuticals, L.P. | Methods for treating attention deficit hyperactivity disorder with methylphenidate |
Non-Patent Citations (1)
| Title |
|---|
| 日薬理誌, vol. 128, JPN6021028523, 2006, pages 8 - 12, ISSN: 0004555393 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2023518871A (ja) * | 2020-03-23 | 2023-05-08 | ジェネンテック, インコーポレイテッド | 深層学習を使用した薬物動態パラメータの推定 |
| JP7577756B2 (ja) | 2020-03-23 | 2024-11-05 | ジェネンテック, インコーポレイテッド | 深層学習を使用した薬物動態パラメータの推定 |
| US12400734B2 (en) | 2020-03-23 | 2025-08-26 | Genentech, Inc. | Estimating pharmacokinetic parameters using deep learning |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20190107655A (ko) | 2019-09-20 |
| AU2017353921A1 (en) | 2019-06-13 |
| US20190314356A1 (en) | 2019-10-17 |
| KR20240033130A (ko) | 2024-03-12 |
| WO2018085256A1 (en) | 2018-05-11 |
| US11166947B2 (en) | 2021-11-09 |
| AU2017353921B2 (en) | 2023-11-09 |
| EP3585439A4 (en) | 2020-07-22 |
| EP3585439A1 (en) | 2020-01-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Derendorf et al. | Rowland and Tozer's clinical pharmacokinetics and pharmacodynamics: concepts and applications | |
| Swanson et al. | A comparison of once-daily extended-release methylphenidate formulations in children with attention-deficit/hyperactivity disorder in the laboratory school (the Comacs Study) | |
| Brody et al. | Cigarette smoking saturates brain α4β2 nicotinic acetylcholine receptors | |
| ES3025836T3 (en) | Use of pridopidine for treating functional decline | |
| Bontempo et al. | D-cycloserine augmentation of behavioral therapy for the treatment of anxiety disorders: a meta-analysis | |
| Gotta et al. | Therapeutic drug monitoring of imatinib: Bayesian and alternative methods to predict trough levels | |
| AU2017315781A1 (en) | Use of pridopidine for treating dystonias | |
| JP2012517449A (ja) | アミノピリジンによる長期治療のための組成物及び方法 | |
| Childress et al. | Single-dose pharmacokinetics of HLD200, a delayed-release and extended-release methylphenidate formulation, in healthy adults and in adolescents and children with attention-deficit/hyperactivity disorder | |
| Sullivan et al. | Opioid use and dropout in patients receiving oral naltrexone with or without single administration of injection naltrexone | |
| Hsu et al. | The influence of light administration on interpersonal behavior and affect in people with mild to moderate seasonality | |
| Fuchs et al. | Efficacy of isolated home blood pressure monitoring for blood pressure control: randomized controlled trial with ambulatory blood pressure monitoring–MONITOR study | |
| JP2020504763A (ja) | メチルフェニデートを用いてadhdを処置するための小児の有効な投薬 | |
| Shram et al. | Differences in the in vitro and in vivo pharmacokinetic profiles of once-daily modified-release methylphenidate formulations in Canada: examination of current bioequivalence criteria | |
| Rajendram et al. | Protocol for the combined immunosuppression & radiotherapy in thyroid eye disease (CIRTED) trial: A multi-centre, double-masked, factorial randomised controlled trial | |
| Abdelgawad et al. | Population Pharmacokinetics of Rifampicin in Plasma and Cerebrospinal Fluid in Adults With Tuberculosis Meningitis | |
| Wang et al. | Vatalanib population pharmacokinetics in patients with myelodysplastic syndrome: CALGB 10105 (A lliance) | |
| Lim et al. | Pharmacokinetic‐pharmacodynamic modeling of intravenous and oral topiramate and its effect on the symbol‐digit modalities test in adult healthy volunteers | |
| Maclean et al. | Quantifying the impact of nonadherence patterns on exposure to oral immunosuppressants | |
| Liu et al. | Population Pharmacokinetics Modeling of Selpercatinib to Support Posology in Pediatric Patients With RET‐Altered Metastatic Thyroid Cancer or Solid Tumors | |
| Johnson et al. | Methods for Assessing the Adherence to Medical Devices | |
| JP7542539B2 (ja) | 注意欠陥多動性障害を処置するためのメチルフェニデート組成物 | |
| Upton | U-RHYTHM microdialysis: towards ambulatory metabolodynamics | |
| Gao et al. | A randomized, open‐label, 3‐way crossover study to demonstrate bioequivalence of sildenafil powder for oral suspension with tablets used commercially and in clinical studies for the treatment of pulmonary arterial hypertension | |
| TW202438060A (zh) | 用於治療夏柯-馬利-杜斯氏症的組成物及方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20191129 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20191129 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20201030 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20201030 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20210715 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210721 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20211020 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20211220 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220121 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20220222 |